Morgan Stanley Issues Positive Forecast for Solventum (NYSE:SOLV) Stock Price

Solventum (NYSE:SOLVGet Free Report) had its target price boosted by stock analysts at Morgan Stanley from $60.00 to $73.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Morgan Stanley’s target price points to a potential upside of 3.26% from the company’s previous close.

Other analysts also recently issued research reports about the stock. The Goldman Sachs Group raised their price target on shares of Solventum from $48.00 to $54.00 and gave the stock a “sell” rating in a report on Monday, August 12th. Piper Sandler lifted their target price on shares of Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a report on Friday, November 8th. Wolfe Research started coverage on shares of Solventum in a report on Thursday, September 26th. They issued a “peer perform” rating for the company. Wells Fargo & Company dropped their target price on shares of Solventum from $69.00 to $64.00 and set an “equal weight” rating for the company in a report on Friday, August 9th. Finally, Stifel Nicolaus started coverage on shares of Solventum in a report on Tuesday, October 8th. They issued a “buy” rating and a $82.00 target price for the company. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, Solventum has a consensus rating of “Hold” and an average target price of $68.00.

Check Out Our Latest Research Report on Solventum

Solventum Stock Performance

Shares of NYSE SOLV opened at $70.70 on Monday. The company has a 50 day simple moving average of $70.23 and a 200-day simple moving average of $62.07. The company has a debt-to-equity ratio of 2.90, a quick ratio of 0.96 and a current ratio of 1.31. Solventum has a 1 year low of $47.16 and a 1 year high of $96.05.

Institutional Investors Weigh In On Solventum

Several institutional investors have recently modified their holdings of the company. Tokio Marine Asset Management Co. Ltd. lifted its position in shares of Solventum by 4.2% during the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,966 shares of the company’s stock worth $346,000 after purchasing an additional 200 shares during the last quarter. National Bank of Canada FI raised its stake in Solventum by 4.0% during the 2nd quarter. National Bank of Canada FI now owns 6,093 shares of the company’s stock worth $314,000 after acquiring an additional 236 shares in the last quarter. IVC Wealth Advisors LLC raised its stake in Solventum by 5.0% during the 3rd quarter. IVC Wealth Advisors LLC now owns 6,649 shares of the company’s stock worth $464,000 after acquiring an additional 318 shares in the last quarter. KKM Financial LLC raised its stake in Solventum by 7.9% during the 3rd quarter. KKM Financial LLC now owns 4,367 shares of the company’s stock worth $304,000 after acquiring an additional 319 shares in the last quarter. Finally, Copeland Capital Management LLC acquired a new stake in Solventum during the 3rd quarter worth $26,000.

About Solventum

(Get Free Report)

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

See Also

Analyst Recommendations for Solventum (NYSE:SOLV)

Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.